OBJECTIVES: Campylobacteriosis is one of the most important human foodborne infections, attributed to broiler chicken consumption in about 30% of cases. In a recently published costutility model of potential Campylobacter control measures in the EU-27, disease burden and cost of illness estimates were driven by data from the Netherlands. The aim of our work was to gather country-specific cost of illness estimates, to generate a conservative estimate of Campylobacter related disease burden expressed in QALYs, and to re-assess the costeffectiveness of control measure options. METHODS: Data from The Netherlands on productivity loss and direct healthcare costs were corrected for country-specific gross average wages and total health expenditure per capita, respectively. Health burden due to acute gastroenteritis, Guillain-Barré syndrome, and reactive arthritis were estimated from published data. Inflammatory bowel disease and irritable bowel syndrome were omitted, in line with a WHO opinion. RESULTS: Based on the adapted model, the EU-wide implementation of the available and acceptable measures against Campylobacter in indoor broiler chicken would be a dominant strategy as compared to the current practice, yielding 26400 QALY gain and 85 million EUR cost saving each year. The expected cost saving is due to the decrease of productivity loss (69%) and direct healthcare costs (31%). As the investigated strategy will not be reimbursed by healthcare payers, the societal perspective is justified. The poster also presents a strategic pricing exercise on bacteriocin treatment in the UK and in Hungary (an intervention option currently under development). CONCLUSIONS: Implementation of the investigated control strategy would be dominant at the EU-27 level. The cost-effectiveness of add-on bacteriocin treatment in the UK could not be justified at the assumed price level. Application of HTA methodology in food safety and nutritional policies could improve public health, and also the allocative efficiency of public health budgets.
Introduction
According to a published cost-utility analysis 1 , the EU-wide implementation of currently available food safety technologies with good consumer acceptance (Figure 1 ) in the food chain of indoor broiler chicken would result in 67,300 annual avoided DALYs and 353 million EUR annual cost savings in the EU-27. These humanistic burden calculations were based on the most pessimistic disease burden estimates in the literature. The economic burden estimates were based on data from The Netherlands. Currently available food safety technologies with good consumer acceptance 1 are highlighted in blue.
A conservative QALY loss estimate of campylobacteriosis
The clinical symptoms of human campylobacteriosis are typically limited to a mild gastroenteritis (GE). However, severe and even fatal GE cases may also occur. Long-term complications are rare but can also be severe/fatal, including Guillain-Barre syndrome and reactive arthritis. Inflammatory bowel diseases and irritable bowel syndrome were raised as potential long-term complications of human campylobacteriosis, but are omitted from this conservative estimate along a recent WHO opinion 5 .
Our results suggest 15.23 QALY loss per 1000 GE cases at a 4% annual discount rate (Figure 2 ). For comparison, note that the EFSA Scientific Opinion estimated 38.9 DALY burden for 1000 GE cases 2 , and about half of that estimate was due to irritable bowel syndrome 3,4 . 
Country-specific cost of illness correction factors
The EFSA Scientific Opinion claimed 2,400 million EUR annual cost for 9 million human campylobacteriosis cases 2 , resulting in a 267 EUR/case estimate. The underlying data from the Netherlands was 177 EUR/case for productivity loss and 82 EUR/case for direct healthcare costs. For country-specific correction factors, annual income per capita (UNECE) and health expenditure per capita (OECD) were applied (Figure 3) . It is apparent that extrapolation of cost of illness data from the Netherlands would lead to an overestimated economic burden estimate in the EU-27. 
Value-based pricing of bacteriocin treatment
The assumed price of bacteriocin treatment is 60 EUR/year/1000 chicken in the published model 1 . According to our adapted estimates, the value based price of bacteriocin treatment could be 50-65 EUR/year/1000 chicken in the UK, and 393-551 EUR/year/1000 chicken in Hungary in the current situation. However, if bacteriocin treatment is introduced as an add-on to the available interventions with good consumer acceptance, the value-based price of bacteriocin treatment could be 25-31 EUR/year/1000 chicken in the UK, and 166-231 EUR/year/1000 chicken in Hungary.
CONCLUSIONS
Implementation of available food safety interventions with good consumer acceptance would be a dominant strategy in the EU-27, as confirmed by our conservative, adapted model results;
Bacteriocin treatment (under development) would not be cost-effective at the assumed price in the UK (as opposed to Hungary) if compared with the combination of available food safety interventions with good consumer acceptance;
Adoption of HTA methodology in the context of food safety and nutrition policies could improve the allocative effectiveness of public health oriented budgets.
